MRNA Moderna Inc

Price (delayed)

$86.99

Market cap

$33.17B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$9.1

Enterprise value

$31.51B

Moderna is an American, Cambridge, Massachusetts-based biotechnology company focused on drug discovery, drug development, and vaccine technologies based exclusively on messenger RNA . The Moderna technology platform is to insert ...

Highlights
The quick ratio has grown by 33% YoY but it has contracted by 23% from the previous quarter
The company's EPS has shrunk by 131% YoY
The net income has plunged by 129% YoY

Key stats

What are the main financial stats of MRNA
Market
Shares outstanding
381.28M
Market cap
$33.17B
Enterprise value
$31.51B
Valuations
Price to book (P/B)
2.46
Price to sales (P/S)
3.63
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.45
Earnings
Revenue
$9.12B
EBIT
-$2.36B
EBITDA
-$1.86B
Free cash flow
-$2.66B
Per share
EPS
-$9.1
Free cash flow per share
-$6.97
Book value per share
$35.35
Revenue per share
$23.94
TBVPS
$51.05
Balance sheet
Total assets
$19.45B
Total liabilities
$6B
Debt
$1.27B
Equity
$13.46B
Working capital
$6.41B
Liquidity
Debt to equity
0.09
Current ratio
2.46
Quick ratio
2.15
Net debt/EBITDA
0.89
Margins
EBITDA margin
-20.4%
Gross margin
37.7%
Net margin
-38%
Operating margin
-29.2%
Efficiency
Return on assets
-15.2%
Return on equity
-20.3%
Return on invested capital
-14.3%
Return on capital employed
-15.6%
Return on sales
-25.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MRNA stock price

How has the Moderna stock price performed over time
Intraday
-1.56%
1 week
1.9%
1 month
-12.75%
1 year
-47.79%
YTD
-12.53%
QTD
-12.53%

Financial performance

How have Moderna's revenue and profit performed over time
Revenue
$9.12B
Gross profit
$3.44B
Operating income
-$2.67B
Net income
-$3.47B
Gross margin
37.7%
Net margin
-38%
The net margin has dropped by 169% year-on-year
Moderna's operating margin has shrunk by 147% YoY
The net income has plunged by 129% YoY
The operating income has plunged by 120% YoY

Growth

What is Moderna's growth rate over time

Valuation

What is Moderna stock price valuation
P/E
N/A
P/B
2.46
P/S
3.63
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.45
The company's EPS has shrunk by 131% YoY
MRNA's P/B is 64% below its 5-year quarterly average of 6.9 and 21% below its last 4 quarters average of 3.1
The equity is down by 25% YoY and by 21% QoQ
The stock's P/S is 93% below its 5-year quarterly average of 49.8 and 11% below its last 4 quarters average of 4.1
MRNA's revenue has dropped by 57% year-on-year and by 14% since the previous quarter

Efficiency

How efficient is Moderna business performance
The company's return on sales has shrunk by 141% YoY
Moderna's ROA has plunged by 134% YoY
MRNA's return on equity has dropped by 129% year-on-year
The ROIC has plunged by 115% YoY

Dividends

What is MRNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MRNA.

Financial health

How did Moderna financials performed over time
The quick ratio has grown by 33% YoY but it has contracted by 23% from the previous quarter
The current ratio has declined by 27% since the previous quarter but it is up by 17% year-on-year
The debt is 91% smaller than the equity
The company's debt to equity has surged by 50% QoQ and by 50% YoY
The debt has grown by 34% since the previous quarter and by 27% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.